within Pharmacolibrary.Drugs.ATC.N;

model N06AX22
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.03,
    Cl             = 0.018333333333333333,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02666666666666667,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06AX22</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Agomelatine is an antidepressant that acts as an agonist at melatonergic MT1 and MT2 receptors and as an antagonist at 5-HT2C serotonin receptors. It is used primarily in the treatment of major depressive disorder in adults. Agomelatine is approved in several countries for clinical use in depression.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters summarized for healthy adult subjects after oral administration as single and multiple doses.</p><h4>References</h4><ol><li><p>Saiz-Rodríguez, M, et al., &amp; Abad-Santos, F (2019). Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics. <i>Journal of psychopharmacology (Oxford, England)</i> 33(4) 522–531. DOI:<a href=\"https://doi.org/10.1177/0269881119827959\">10.1177/0269881119827959</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30789308/\">https://pubmed.ncbi.nlm.nih.gov/30789308</a></p></li><li><p>Song, L, et al., &amp; Wang, L (2014). Effect of CYP1A2 polymorphism on the pharmacokinetics of agomelatine in Chinese healthy male volunteers. <i>Journal of clinical pharmacy and therapeutics</i> 39(2) 204–209. DOI:<a href=\"https://doi.org/10.1111/jcpt.12118\">10.1111/jcpt.12118</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24372004/\">https://pubmed.ncbi.nlm.nih.gov/24372004</a></p></li><li><p>Prajapati, JB, et al., &amp; Patel, AA (2018). Oral bioavailability enhancement of agomelatine by loading into nanostructured lipid carriers: Peyer&#x27;s patch targeting approach. <i>International journal of nanomedicine</i> 13(T-NANO 2014 Abstracts) 35–38. DOI:<a href=\"https://doi.org/10.2147/IJN.S124703\">10.2147/IJN.S124703</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29593392/\">https://pubmed.ncbi.nlm.nih.gov/29593392</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06AX22;
